A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 769,300 shares of FOLD stock, worth $7.53 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
769,300
Previous 632,024 21.72%
Holding current value
$7.53 Million
Previous $6.27 Million 31.06%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$9.55 - $12.09 $1.31 Million - $1.66 Million
137,276 Added 21.72%
769,300 $8.22 Million
Q2 2024

Aug 09, 2024

SELL
$9.04 - $11.75 $2.93 Million - $3.81 Million
-324,176 Reduced 33.9%
632,024 $6.27 Million
Q1 2024

May 13, 2024

BUY
$11.43 - $14.24 $10 Million - $12.5 Million
878,800 Added 1135.4%
956,200 $11.3 Million
Q4 2023

Feb 13, 2024

SELL
$9.97 - $14.52 $707,870 - $1.03 Million
-71,000 Reduced 47.84%
77,400 $1.1 Million
Q3 2023

Nov 14, 2023

BUY
$11.78 - $13.86 $1.75 Million - $2.06 Million
148,400 New
148,400 $1.81 Million
Q1 2023

May 12, 2023

BUY
$10.91 - $13.54 $4.24 Million - $5.27 Million
389,000 New
389,000 $4.31 Million
Q3 2022

Nov 14, 2022

BUY
$9.82 - $12.75 $2.8 Million - $3.63 Million
284,800 New
284,800 $2.97 Million
Q1 2020

May 14, 2020

SELL
$6.63 - $11.16 $860,932 - $1.45 Million
-129,854 Closed
0 $0
Q4 2019

Feb 13, 2020

SELL
$7.48 - $10.75 $10 Million - $14.4 Million
-1,340,946 Reduced 91.17%
129,854 $1.27 Million
Q3 2019

Nov 13, 2019

BUY
$8.02 - $13.25 $9.76 Million - $16.1 Million
1,217,000 Added 479.51%
1,470,800 $11.8 Million
Q2 2019

Aug 12, 2019

BUY
$10.96 - $14.4 $2.78 Million - $3.65 Million
253,800 New
253,800 $3.17 Million

Others Institutions Holding FOLD

About AMICUS THERAPEUTICS, INC.


  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.75B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.